gdc

Web Exclusives

Can Artificial Intelligence Help Win the Fight Against Breast Cancer?
Breast Cancer
Machines that use artificial intelligence—such as Siri and Alexa—have become part of our everyday lives. Could this technology help in the fight against breast cancer? See how human doctors stacked up against machines in one study.
Leukemia
Ibrutinib is an orally administered Bruton tyrosine kinase inhibitor used in the treatment of patients with CLL. Because ibrutinib has been prescribed in the United States for several years, researchers sought to learn how the rates of side effects in the “real world” compared with those reported in clinical trials.
Leukemia
When treating patients with CLL, understanding specific details about the disease helps doctors as they choose among available treatments. CLL experts believe that conducting specific blood tests before prescribing each patient’s treatment is critical. Do all doctors who treat patients with CLL also appreciate this need for testing?
Leukemia
In a large clinical trial, ibrutinib was shown to be effective in delaying disease progression in patients with early-stage, high-risk CLL who did not yet have symptoms. Researchers are now conducting clinical trials to determine the safety and efficacy of next-generation drugs and combinations in patients with early-stage, high-risk disease.
Leukemia
In the era of targeted treatments for CLL, should patients with early-stage disease be placed on therapy before they experience symptoms? Doctors continue to debate this question while waiting for clinical trial data to evolve.
Leukemia
Chronic lymphocytic leukemia (CLL) is a type of blood cancer. Some patients with CLL may not need treatment right away, whereas others require more urgent attention. How do cancer specialists decide when to start patients on therapy?
Leukemia
There are important changes to beneficiaries’ Medicare Part D prescription drug coverage for 2020. These changes can affect how much patients must pay out of pocket for their medications, including certain cancer drugs.
Leukemia
In an updated analysis of 134 patients with relapsed/refractory chronic lymphocytic leukemia (CLL) who were treated with acalabrutinib monotherapy, more than 90% were still responding after 41 months of treatment.
Leukemia
Patients with chronic lymphocytic leukemia or mantle-cell lymphoma who were started on acalabrutinib in the United States had high rates of comorbid hypertension and other hematologic malignancies, and about two-thirds received prior ibrutinib.
Leukemia
In shared decision-making, patients communicate their preferences and values to their healthcare team when treatment decisions are made. Patients who take an active role in the process tend to be more satisfied with their quality of care.
Page 4 of 15
Results 31 - 40 of 142

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country